stelauguqdinec.blogspot.com
Valentino was most recently president and CEO ofNew Jersey-base , which was acquired in 2008 by British firm Recketty Benckiser. He has held management positions with major drug including Alpharma, Novartis, Pharmacia/Upjohn and Warner Lambert. Valentino replaces Williamj Nuerge, who was named CEO of Xanodyne in 2004 and left the compan yin 2007. Xanodyne’s prioritiea will be to bring to market its Zipso acutepain treatment, and a drug in development for heavy menstrual bleeding, Valentinoi said in a news release. The company also said it completef $38 million in equity financing, led by , a Boston-basec health care equity firm.
Other investors in the company includAIG Investments’ sponsored funds, Aisling Capital, Blue Chip Venturde Co., Essex Woodlands, HealthCars Ventures LLC and Union Springs. “Mike bringd major pharmaceutical and commercial experiencwe to the team while the financinv brings critical resources needed forthe launches,” said Rolf board chairman, in the Xanodyne, based in Newport, is a specialt y pharmaceutical company focused on treatmentsa for women’s health care and pain
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment